Kura Oncology (KURA) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. SPOT
6. BYD
7. WCN
8. SPY
9. BE
10. IVBIY

Go back to Kura Oncology (KURA) Tops Q2 EPS by 1c

Kura Oncology Reports Second Quarter 2023 Financial Results

August 3, 2023 4:05 PM EDT

Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections

First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML

Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA

Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC

First-in-human study of next-generation FTI KO-2806 to begin in second half of 2023

$477 million in cash, equivalents and investments provide runway to mid-2026

Management to host webcast and... More